Please provide your email address to receive an email when new articles are posted on . SEATTLE — The effects of aflibercept treatment in the three arms of the PULSAR study were not affected by ...
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
We look forward to conducting this study with Verily and incorporating the learnings to advance oral and overall healthcare.” The study will enroll current participants in Verily’s ongoing Baseline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback